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Objective: To perform a meta-analysis to determine the effect of loco-regional radiation therapy (RT)
compared to no loco-regional RT for operated patients in clinical stage cN2 breast cancer at diagnosis and
ypN0 after preoperative chemotherapy (PST).
Material and Methods: Eligible studies were identified through a systematic search of the medical
literature performed independently by two researchers using a validated search strategy. An electronic
search of Medline via PubMed and Embase (Breast cancer AND preoperative chemotherapy AND radi-
ation therapy) was conducted with no language or publication status restrictions. The effect of loco-
regional RT on overall (OS), disease free (DFS), loco-regional recurrence-free (LRRFS) survival and local
recurrence was evaluated. An electronic search of Medline via PubMed and Embase (Toxicity AND ra-
diation therapy breast cancer AND preoperative therapy; toxicity AND breast surgery AND preoperative
chemotherapy) was conducted for outcomes of harm: major acute and late skin toxicity, lymphedema
and cardiac events.
Results: Of 333 studies identified, 4 retrospective studies reporting on a total of 1107 patients were
included in the meta-analysis. Six and 3 reported data of acute and late skin toxicity, while 2 studies
provided information on cardiac events. Pooled results showed no difference in terms of hazard ratio for
loco-regional RT versus no loco-regional RT [hazard ratio (HR) ¼ 0.82, 95% confidence interval (CI) 0.63
e1.68]. Loco-regional RT was associated with an OS benefit in the subgroup analysis: IIIB-C (loco-regional
RT 79.3% vs no loco-regional RT 71.2%, p ¼ 0.027) and T3-T4 (loco-regional RT 82.6% vs no loco-regionalmelli.it (V. Lancellotta).
r Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
L. Marino, V. Lancellotta, P. Franco et al. The Breast 55 (2021) 119e127RT 76.6%, p ¼ 0.025). No difference was shown in terms of 5-year DFS (loco-regional RT 91.2% vs no loco-
regional RT 83%, p ¼ 0.441) and LRRFS (loco-regional RT 98.1% vs no loco-regional RT 92.3%, p ¼ 0.148).
There was no significant difference between the groups in terms of acute and late skin toxicities, lym-
phedema and cardiac events.
Conclusions: Because of the limitations due to the small number of studies and heterogeneity in the
analysis, the present study does not allow to draw any definitive conclusion, highlighting the need for
well-controlled trials to determine the effect of loco-regional RT in patients with cN2 having a patho-
logical complete response in the axillary nodes after preoperative chemotherapy.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Preoperative chemotherapy (PST) in breast cancer (BC) patients
was historically used in locally advanced disease. More recently, it
is increasingly being applied in earlier stage BC, although no
advantage in survival was observed as compared to postoperative
systemic therapy [1e4]. Several studies showed a survival benefit in
patients with pathological complete response (pCR), except for
luminal A-patients [5,6] suggesting that the response to PST may
have clinical implications such as a higher chance to offer breast
conserving therapy [7,8] and a less extensive treatment of the axilla,
if after PST, tumor-positive (axillary) lymph nodes are converted
into ypN0 [7,9e12]. It means that it is possible to modulate post-
operative treatments according to the response to PST, for specific
biological types. An example could be intensification of post-
operative treatment with TDM1 for Stage I eII, HER2 positive
(HER2þ) disease achieving less than pCR after PST [13]. Random-
ized trials have established that administration of loco-regional
radiation therapy (RT) to appropriately selected women who
receive postoperative chemotherapy after mastectomy reduces
loco-regional recurrence and breast cancer mortality [13e16]. The
large grey area includes the role of loco-regional irradiation in
breast cancer patients with cN2 at diagnosis and achieving a pCR in
the axillary nodes (ypN0) after PST because no randomized trials
have been performed to define which patients benefit from loco-
regional RT after PST.
Pathologic downstagingmight include complete response of the
primary tumor and/or axillary disease and thus the conventional
role of loco-regional RT may not be clear [17,18]. Several studies120showed that the recurrence risk is influenced by tumor biology and
by both the pre-and post PST tumor stage [19e25] suggesting the
use of loco-regional RT in patients with cT3N þ disease, or pa-
tients with cT1-4N2 disease regardless of their response to PST
[26]. An analysis of the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-18 and B-27 PST trials identified initial clinical
stage and response to therapy as significant predictors for local-
regional recurrence (LRR) patients receiving mastectomy, none of
whom received loco-regional RT [27]. Although pCR has been
associated with improved survival, the association is stronger in
triple-negative and HER2þ hormone receptor (HR)-negative pa-
tients who received an anti-HER2 therapy [28,29]. Therefore, rec-
ommendations for loco-regional RT in specific subtypes could
result in overtreatment [30,31].
Due to these uncertanties, the Association of Radiation and
Clinical Oncology (AIRO) Guidelines decided to develop a clinical
recommendation on this topic (patients with breast cancer cN2 at
diagnosis turning ypN0 after preoperative chemotherapy), based
on the Grades of Recommendation, Assessment, Development, and
Evaluation (GRADE) approach.2. Materials and methods
2.1. Development of clinical questions
The clinical question was developed following the P.I.C.O.
acronym, as follow: population (P), intervention (I), comparison (C),
and outcomes (O). For the 2019 version of AIRO guidelines on breast
cancer, the panel expressed the following clinical question:
L. Marino, V. Lancellotta, P. Franco et al. The Breast 55 (2021) 119e127(P) In operated breast cancer patients with cN2 at diagnosis and
ypN0 after PST, is loco-regional RT (I) superior when compared to
no loco-regional RT (C), in relation to the outcomes (O) of benefit
and harm. Development of GRADE (Grades of Recommendation,
Assessment, Development and Evaluation) Recommendation by
the Italian Association of radiation therapy and Clinical Oncology
(AIRO).
2.2. Identification of outcomes
The panel identified the following outcomes of benefit: overall
(OS), breast cancer specific (BCSS), disease free survival (DFS) and
local control (LC). The following outcomes of harm were identified
by the panel: acute and late skin toxicities, lymphedema, lung and
heart grade 3e4 toxicities. All these outcomes were considered as
“critical” for the decision-making process.
2.3. Search strategy and selection of evidence
This systematic review was conducted in accordance with the
PRISMA guidelines [32]. We performed a comprehensive literature
search using PubMed and Embase (up to July 2019) to identify the
full articles evaluating the efficacy and the safety of loco-regional
RT in breast cancer patients with cN2 at diagnosis and turning
ypN0 after neo-postoperative chemotherapy. ClinicalTrials.gov was
searched for ongoing or recently completed trials, and PROSPERO
was searched for ongoing or recently completed systematic re-
views. Electronic searches were supplemented by manually
searching the references of included studies and review articles.
The studies were identified using the following medical subject
headings (MeSH) and keywords including “breast neoplasms”,
“preoperative chemotherapy”, “postoperative radiation therapy”,
“toxicity”. The Medline search strategy was (“breast neoplasia”
[Mesh] OR “breast neoplasia” [All fields]) AND (“preoperative
therapy” [Mesh] OR “preoperative therapy” [All fields]), AND “ra-
diation therapy” [Mesh] OR “radiation therapy” [All fields]) AND
“toxicity” [Mesh] OR “toxicity” [All fields]). The search was
restricted to English language.
We analyzed only clinical studies presented as full texts and
investigating the population of breast cancer patients with cN2 at
diagnosis and ypN0 after PST, who underwent loco-regional RT.
Conference papers, surveys, letters, editorials, book chapters,
and reviews were excluded. Time restriction (1990e2019) of the
publication was considered.
Studies were identified on a search process performed by two
independent reviewers (VL, LM), and uncertainty regarding eligi-
bility was resolved by consulting a third reviewer. Eligible citations
were retrieved for full-text review. Finally, a committee including
members of the AIRO Task Force performed an independent check
and the definitive approval of the review.
Inclusion criteria for the meta-analysis were: (1) randomized-
controlled trials (RCTs), prospective, retrospective, and cohort
studies; (2) utilization of PST in cN2; (3) patients receiving or not
postoperative RT; (5) reported quantitative outcome data. The
following information and data were extracted from studies that
met the inclusion criteria: the name of the first author, year of
publication, study design, number of patients in each group and
outcome data.
The meta-analysis was conducted in accordance with the rec-
ommendations made by the Cochrane Collaboration as well as the
PRISMA statement. Hazard ratio (HR) was used as effect measure
for time-to-event outcomes [OS and DFS] in two studies. Meta-
analysis was conducted using a random effects model. We
assessed statistical heterogeneity with I2 statistics. This method
describes the proportion of total variation between included121studies that are attributable to differences between studies rather
than sampling error (chance). Statistical heterogeneity between
groups was considered relevant for comparisons with I2 statistics of
>50%.
The GRADEpro Guideline Development Tool (GDT) was used to
create Summary of Findings (SoF) tables in Cochrane systematic
reviews.
2.4. Quality of evidence evaluation
Certainty of evidence for all selected outcomes was performed
according to the GRADE approach, considering study limitations,
imprecision, indirectness, inconsistency and publication bias. Cer-
tainty level starts at higher pre-specified level for randomized
controlled trials, but levels of certainty can be downgraded if lim-
itations in one of the abovementioned domains are detected. Evi-
dence can be classified as high, moderate, low and very low level of
certainty.
2.5. Benefit/harm balance and clinical recommendation
Based on the summary of evidence, the panel expressed one of
the following judgments about the benefit to risk ratio between
intervention and comparison: favorable, uncertain/favorable, un-
certain (both for intervention or comparison), uncertain/unfavor-
able, and unfavorable. The strength of the recommendation could
be considered as strong positive, conditional positive, uncertain,
conditional negative or strong negative.
3. Results
3.1. Search strategy results and details of the identified relevant
studies
A flow diagram of study selection for primary outcomes (benefit
outcomes) is shown in Fig. 1. A total of 333 potentially relevant
studies was identified through the database searches after dupli-
cates removal. These articles were screened by title and abstract
and 246were excluded. Of these, 83 articles were excluded because
of few numbers of patients (<50 patients) and lack of comparison
group (Fig. 1), leaving four studies for the analysis [31,33e35].
The retrospective study of Kantor et al. evaluated the role of
loco-regional RT in the subgroup of patients that were ypN0 after
PST [33]. About 698 patients (8.4%) had a complete response to PST
in the breast and 1937 (23.3%) had tumor-negative axillary nodes
after PST. Four hundred-six patients were cN2, of these 41 (40.1%)
received ENI while 32 patients (20.1%) underwent exclusive
surgery.
The retrospective study of Liu et al. [34] evaluated the role of
loco-regional RT after mastectomy vs non-loco-regional RT on a
cohort of 251 breast cancer patients with cN2 at diagnosis and
ypN0 after PST. Of the 251 cN2 patients, 90 (of n ¼ 657) (13.1%)
underwent loco-regional RT and 161 (of n ¼ 903) (17.8%) did not.
Irradiated patients had less comorbidities; more advanced stage, a
higher number of regional lymph nodes examined, and less un-
known ER/PR status, and were more likely to receive multi-agent
chemotherapy or endocrine therapy. Target volumes included
chest wall and lymph nodes, with or without a boost to the chest
wall. The median RT dose was 50.4 Gy.
The KROG 12-05 [35] study is a retrospective trial that evaluated
the role of loco-regional RT in patients undergoing mastectomy vs
non-loco-regional RTon a sample of 151 breast cancer patients with
cN2 at diagnosis. The most common PST regimen was a combina-
tion of anthracycline and taxane (55.6%), followed by
anthracycline-based (36.4%) and taxane-based (6.0%)
Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Flow chart for outcomes of benefit.
L. Marino, V. Lancellotta, P. Franco et al. The Breast 55 (2021) 119e127chemotherapy. Three patients (2%) received a different regimen. All
patients underwent mastectomy. Complete axillary lymph node
dissection was performed in 141 patients (93.4%) and sentinel
lymph node biopsy alone was performed in 10 (6.7%). Seventy-two
(47.6%) and 19 patients (12.6%) received postoperative hormonal
therapy and targeted therapy, respectively. The radiation target
volumes were the chest wall and regional lymph-nodes (axilla and
supraclavicular fossa, with or without the internal mammary
chain). A total RT dose of 45e50 Gy was delivered.
The KROG 16-16 study attempted to investigate the potential
subgroups (as cN2 and cT3-4) that would benefit ENI, in ypN0 as
after PST and breast-conserving surgery [31]. Seventy-three pa-
tients were cN2, of these 41 (40.1%) received ENI while 32 patients
(20.1%) did not. The most frequent PST regimen was anthracycline
plus taxane (41.0%), followed by anthracycline with cyclophos-
phamide combined with taxane (32.2%) and anthracycline in
combinationwith cyclophosphamide (11.5%). Axillary lymph-nodes
(LN) fine-needle aspiration before PST was performed in 107 pa-
tients (41.0%). Axillary LN dissection (ALND) was performed in 213
patients (81.6%), while 48 patients (18.4%) received sentinel LN
biopsy (SLNB) alone. Postoperative hormone treatment was
administrated to 86 patients (33.0%). HER2-targeted therapy was
offered to 48 patients (50.2%).
The postoperative RT dose to the whole breast was 45e54 Gy
given in 1.8e2.0 Gy per fraction. Boost RT to the primary tumor bed
was delivered in 233 patients (89.3%). ENI including the supra-
clavicular region was performed in 102 patients (39.1%), of whom
20 (7.7%) received internal mammary irradiation. The RT dose for
ENI was 45e54 Gy given in conventional fractionation.
A flow diagram regarding the study selection for outcomes of122harm is shown in Fig. 2. A total of 200 potentially relevant studies
were identified through the database searches after duplicates
were removed. These articles were screened by title and abstract
and 176 were excluded. The remaining full-text articles were
reviewed and 17were excluded, the reasons for which are shown in
Fig. 2. Thus, ultimately, seven articles were included in the meta-
analysis [31,37e42] and all studies were retrospective.3.2. Outcomes of benefit
All the four identified studies reported OS rates. Three out of
four studies showed that loco-regional RT in breast cancer patients
with cN2 at diagnosis who experience ypN0 after PST did not
improve OS [31,33,35] while only Liu et al. showed a significant
advantage for loco-regional RT in patients with breast staged as
IIIB-IIIC or T3/T4 (HR for patients receiving RT 0.82 (0.63e1.068).
Only two studies reported CSS rates, showing that loco-regional
RT did not improve CSS [31,35].
The LC rates were reported in two studies that showed loco-
regional RT not to improve LC [35,36].
Finally, only two studies reported DFS rates showing that loco-
regional RT did not improve it [35,36].
The Summary of Findings (SoF) tables for outcomes of benefit
was reported in Table 1.
The certainty of evidence was judged as “very low” for each
outcomes of benefit for the following reasons: indirectness for
population including both cN1 and cN2 [35,36] or stage II and II
[34], imprecision for small population [35] or CI including both
effect and no-effect [35,36] or finally to possible selection bias due
to a sub-group analysis of a large database [33].
Fig. 2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Flow chart for outcomes of harm.
Table 1
Summary of findings (SoF) table for outcomes of benefit.
Study design Risk of bias Inconsistency Indirectness Imprecision N. of patients Effect Certainty
PMRT no PMRT Relative (95% CI) Absolute (95% CI)
OS (Shim, Int J Radiation Oncol Biol Phys 2014) (follow-up: median 59 months; assessed with: events)
Observational Not serious Not serious Seriousa Seriousb 5-years OS: RT: 93.3% vs no RT 89.9% (p ¼ 0.443) Very low
OS (Liu, Oncotarget, 2015) (follow-up: median 56 months; assessed with: HR)
Observational Not serious Not serious Seriousc Seriousd HR for RT: 0.82 (0.63e1.068)
SUB-GROUP ANALYSIS: 5-years OS IIIB-IIIC: RT 79.3% vs no RT
71.2% (p ¼ 0.027); 5-years OS T3-T4: RT: 82.6% vs no RT 76.6%
(p ¼ 0.025)
Very low
OS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months)
Observational Not serious Not serious Seriousa Seriousd HR for RT: 0.350 (0.096e1.272) Very low
OS (Kantor, J Surg Oncol, 2017) (follow-up: median 69 months; assessed with: HR)
Observational Seriouse Not serious Not serious Not serious 5-years OS: RT 92.9% vs no RT 83% (p ¼ 0.441) Very low
DFS (Shim, Int J Radiation Oncol Biol Phys 2014) (follow-up: median 59 months; assessed with: KM)
Observational Not serious Not serious Seriousa Seriousb 5-years DFS: RT 91.2% vs no RT 83% (p ¼ 0.441) Very low
DFS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months; assessed with: HR)
Observational Not serious Not serious Seriousa Seriousd HR: 0.561 (0.249e1.264) Very low
LRRFS (Shim, Int J Radiation Oncol Biol Phys 2014)
Observational Not serious Not serious Seriousa Seriousb 5-years LRRFS: RT 98.1% vs no RT 92.3% (p ¼ 0.148) Very low
LRRFS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months; assessed with: HR)
Observational Not serious Not serious Seriousa Seriousd HR: 0.310 (0.148e1.833) Very low
Abbreviations: RT: radiotherapy; OS: overall survival; DFS: disease free survival; LRRFS: loco-regional recurrence-free; HR: hazard ratio; CI: confidence interval; RR: risk ratio;
PST: preoperative chemotherapy.
Explanations.
a Indirectness for population, included both cN1 and cN2 diagnosis downstaged to ypN0 after PST.
b Small population.
c Indirectness for population, included both in Stage II and III.
d CI both included effect and no effect.
e Possible selection bias due to a sub-group analysis of large database.
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Fig. 3. Forest Plots for Outcomes of Harm. a. Acute skin toxicity. b. Late skin toxicity. c. Lymphoedema. d. Late lung toxicity. e. Cardiac events.
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Six studies reported data on acute skin toxicity (grade 3 and 4)
[36e39,41,42]. Three studies reported data of late skin toxicity
(grade 3 and 4), lymphedema and late lung toxicity [36,40,42].
Significant heterogeneity was found for acute skin toxicity with
222 events, pooled analysis 11% (95% CI 6.1e17%, I2 ¼ 97%) (Fig. 3a),
late skin toxicity with 8 events, pooled analysis 0.5% (95% CI 0.1e1%,
I2 ¼ 61%) (Fig. 3b), lymphedema with 24 events, pooled analysis
1.3% (95% CI 0.2e6%, I2¼ 78%) (Fig. 3c) and late lung toxicity with 49
events, pooled analysis 4.5% (95% CI 1.1e7.8%, I2 ¼ 97%) (Fig. 3d).
Pooled results of the two studies that reported cardiac data
showed no difference in the odds of events between patients
treated with RT and those who did not receive RT (24 events,
pooled analysis 1.6% (95% CI 0.3e5%, I2 ¼ 86%) (Fig. 3e).
Summary of Findings (SoF) tables for toxicity was reported in
Table 2.3.4. EtD (evidence to decision) framework
The proposed intervention (loco-regional radiation therapy)
compared to the control (observation) increases, ‘per se’, the inci-
dence of side effects, with a benefit that the poor reliability of the
data makes not substantially evident. In the setting of patients with
pN2 disease after breast surgery and axillary clearance, receiving
postoperative chemotherapy, radiation therapy has proven effec-
tive in reducing local recurrences and possibly improving survival.
It is also evident that the use of preoperative chemotherapy can
select, based on the pathological response, the patients with the
best prognosis, even if robust data on local control are missing.
These considerations make it difficult to suggest anTable 2
Summary of findings (SoF) table for outcomes of harm.
Study design Risk of bias Inconsistency Indirectness Imprecision
6 sudies; Adjuvant RT; acute grade 3e4 toxicity
Observational Not serious Seriousa Not serious Not serious
3 studies; Adjuvant RT; late grade 3e4 skin toxicity
Observational Not serious Seriousb Not serious Not serious
3 studies; Adjuvant RT; late grade 3e4 lung toxicity
Observational Not serious Seriousa Not serious Not serious
3 studies; Adjuvant RT; late grade 3 lymphedema
Observational Not serious Seriousc Not serious Not serious
2 studies; Adjuvant RT; cardiac events
Observational Not serious Seriousd Not serious Not serious











VERY LOW In patients with cN2 at diagnosis turning ypN0 at surgery after preop
radiation therapy (LCRT) may be at the discretion of the patient and c
within a multidisciplinary team
125postoperative strategy including radiation therapy for the patients
included in the developed question, and suggests a case-by-case
evaluation by the clinician based on the biological phenotype (i.e.
luminal-like type vs triple negative, HER2-positive) and specific
clinical characteristics (tumor extension at diagnosis and residual
disease after preoperative treatment).3.5. Benefit/harm balance and final recommendation
The panel voted for the benefit/harm benefit as uncertain. The
strength of the recommendation was voted as conditionally weak
by 5 out of 5 panel members. Hence, the final recommendation
released by the panel was: in patients with cN2 at diagnosis turning
ypN0 at surgery after preoperative chemotherapy, loco-regional RT
may be at the discretion of the patient and clinician after extensive
discussion preferably within a multidisciplinary team (Table 3).4. Discussion
The AIRO Clinical Practice Guidelines on Breast Cancer panel
cannot suggest the use of loco-regional RT in breast cancer patients
with cN2 at diagnosis turning ypN0 after PST.
This is underlined by the lack of data on the role of postoperative
radiation therapy after PST for breast cancer based on treatment
response. While the prognostic impact of pCR after PST on DFS and
OS has been shown in meta-analyses of randomized phase III trials
[43], the association of treatment response with loco-regional
recurrence has been studied only in retrospective reports [44].
Heterogeneity in treatment protocols, inclusion in the target
volume of the IMN, and selection bias could affect the effective role
of RNI in this setting of patients. The only powered analysis usingN. of patients Effect Certainty
PMRT no PMRT Relative (95% CI) Absolute (95% CI)
6 studies with 222 events; pooled analysis 11% (95% CI 6.1e17%).
I2:97%
Very low
3 studies with 8 events; pooled analysis 0.5% (95% CI 0.1e1%).
I2:61%
Very low
3 studies with 49 events; pooled analysis 4.5% (95% CI 1.1e7.8%).
I2:97%
Very low
3 studies with 24 events; pooled analysis 1.3% (95% CI 0e2.6%).
I2:78%
Very low





erative chemotherapy, post mastectomy
linician after extensive discussion preferably
Conditional both for intervention
and comparator
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patient characteristics [45] is compromised by missing details on
the treatment fields and target volumes, as well as missing infor-
mation on LRRFS and DFS. For all these reasons, the role of loco-
regional RT in breast patients with cN2 at diagnosis and ypN0 af-
ter PST is controversial. Indeed, few studies showed as in patients
with clinical stage III disease loco-regional RT seem to have a sig-
nificant benefit even in the setting of a pCR [24] while others failed
to show a benefit for RNI in this subgroup. However, some of these
studies included a significant number of patients with clinically
unsuspicious lymph nodes and were statistically underpowered.
Due to the retrospective nature of the included studies, the quality
of evidence is poor. Since several randomized controlled studies
have shown a benefit of RNI in patients with limited or no nodal
involvement and further risk factors treated with up-front surgery
[46,47], RNI should be strongly considered in patients with clini-
cally involved lymph nodes regardless of the response to PST,
especially in the presence of further risk factors (e. g. young age, ER/
PR-negative, lympho-vascular invasion, residual tumor in the
breast).
In the present analysis loco-regional RT was found to be safe.
Wang et al. [37] found grade 3 acute skin toxicity equal to 8% (32
patients) and symptomatic radiation pneumonitis occurring in less
than 5% of patients. Late skin toxicity and symptomatic lung fibrosis
were uncommon. Early grade 3 skin toxicity was observed in 4.5%
(43 cases) and increased with concomitant chemotherapy
(P < 0.001) and smoking (P ¼ 0.06). Only three patients developed
ischemic heart disease: all were treated with anthracycline-based
CT with or without trastuzumab, and irradiated to the left chest
wall and LN. They all presented numerous cardiovascular risk fac-
tors (2e4 factors). Another risk factor was the use of bolus in loco-
regional RT which correlated with a higher rate of acute grade 2
skin toxicity [38,40]. Loco-regional treatment with IMRT technique
can reduce the incidence rate of radiation toxicity by decreasing
organs at risk (OARs) irradiation [37,39].
The current study has a number of limitations that deserve
consideration. The number of included studies was small, especially
for the secondary outcome measures, and all studies were non-
randomized. This has implications on the results because non-
randomized studies carry a number of inherent biases. Non-
randomized trials do not use concealed randomization; hence,
the groups may not be comparable, leading to selection bias. In
addition, the presence of other confounding factors such as unad-
justed background variables, detection, and recall bias due to se-
lective reporting, or the presentation of incomplete outcome data,
may affect the results of the analysis. These are all potential biases
that may influence the validity of the study results. On the other
hand, the quality assessment indicated that the studies were of
moderate to high quality. No control for patient comorbidities was
included in the analysis. Because of the small number of studies,
important subgroup analyses could not be performed, e.g. clinic-
pathologic factors, hormonal receptor status, and Her2/neu sta-
tus, which are known to be associated with treatment efficacy, was
missing in some patients. The toxicity data were extrapolated from
retrospective studies with different outcomes and some with short
follow-up. A median follow-up of 5 years is insufficient to allow for
the assessment of all potential late toxicities. However, longer
follow-up is unlikely to lead to the detection of further differences
in late toxic effects between the two groups.
5. Conclusions
Because of the limitations due to the small number of studies
and the heterogeneity in treated patients, the panel is not able to
draw any definitive conclusions and highlights the need for well-126controlled trials to determine the effect of RT in patients with
cN2 and ypN0 after PST. The final recommendation released by the
panel was: in patients with cN2 at diagnosis and ypN0 at surgery
after PST, loco-regional RT should be evaluated for each patient
after extensive discussion in the multidisciplinary team. In dis-
cussion with patients, the following aspects should be highlighted:
 The prognosis with and without treatment;
 The limited evidence on the benefit derived from radiant
treatment;
 The risks and benefits including late cardiac and pulmonary
events and possible side effects on reconstruction, when
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